Current Treatment Landscape for mHSPC

Dr Daniel George talks about the current treatment landscape of mHSPC, emphasizing on the advances in the treatment of mHSPC and focusing on clinical trials like ENZAMET, PEACE-1, and ARASENS. Recently, a combincation therapy of darolutamide, ADT and docetaxel has became the standard of care of mHSPC, owing to its high efficacy and good safety profile. The combination of darolutamide with ADT and docetaxel improved overall survival, clinical relevant secondary endpoints and a reduced risk of death. Additionally, the adverse effects associated with this combination shows a similar incidence between treatment arms, demonstrating a good safety profile.